Kauh John Saewook M.D. 4

What Happened
Dr. John Saewook Kauh, M.D., Chief Medical Officer of Tvardi Therapeutics (TVRD), was granted a derivative equity award on January 29, 2026 for 45,000 shares. The Form 4 lists the acquisition price as $0.00, so no cash was paid at grant; the award is reported as a derivative (an option).

Key Details

• Transaction date: 2026-01-29; Form 4 filed 2026-02-02 (reporting date vs. filing date shown on accession record).
• Grant type: Derivative award (option) for 45,000 shares; reported acquisition price $0.00 (total $0 reported).
• Vesting: Shares/options vest in equal monthly installments over 48 months beginning January 29, 2026, subject to continuous service (per footnote).
• Shares owned after transaction: Not specified in the provided summary—see the full Form 4 for total holdings and any other holdings disclosures.
• No additional footnotes (e.g., 10b5-1, tax withholding) were provided beyond the vesting schedule.

Context
This is a standard long-term incentive grant to an executive and is reported as a derivative (option) award that vests monthly over four years. Such grants are common as retention and performance incentives; they do not represent an immediate purchase or sale of underlying shares until vested and exercised. For full legal and ownership details (exercise price, plan terms, and total holdings), consult the complete Form 4 filing (Accession: 0002064881-26-000002).